



Attorney's Docket No.: 18852-002002/5202B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stephen R. Hanson Art Unit : 1615
Serial No. : 10/603,401 Examiner : Thurman K. Page
Filed : June 25, 2003 Conf. No. : 3459
Cust. No. : 20985
Title : METHODS AND COMPOSITIONS FOR TREATING PLATELET-
RELATED DISORDERS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, replacement copy of a Form PTO-1449 (4 pages) that was previously submitted with the Information Disclosure Statements filed on July 25, 2006 and June 25, 2003, copy of Form PTO-892 (1 page) and initialed Forms PTO-1449 (8 pages) filed in relation to US application serial No. 09/666,223, a copy of the cover pages of US Patent No. 6,585,995 (3 pages), and a return postcard for filing in connection with the above-captioned application.

It is respectfully submitted that no fee should be due for this resubmission. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:

- The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,



Stephanie Seidman
Reg. No. 33,779


Attorney Docket No. 18852-002002/5202B

Address all correspondence to:

Stephanie Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
email: seidman@fr.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"Express Mail" Mailing Label Number EV 740119550 US
Date of Deposit November 1, 2006

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.



Stephanie Seidman



Attorney's Docket No.: 18852-002002/5202B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stephen R. Hanson Art Unit : 1615
Serial No. : 10/603,401 Examiner : Thurman K. Page
Filed : June 25, 2003 Conf. No. : 3459
Cust. No. : 20985
Title : METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§1.97-1.98

Because this Supplemental Information Disclosure Statement is providing a replacement copy of a Form PTO-1449 that was previously submitted with the Information Disclosure Statements filed on July 25, 2006 and June 25, 2003, it is respectfully submitted that no fee should be due for this resubmission. However, should it be determined that a fee for resubmitting these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby resubmits this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. This resubmission provides a replacement copy of a Form PTO-1449 (4 pages) that was previously submitted with the Information Disclosure Statements filed on July 25, 2006 and June 25, 2003 in connection with the above-captioned application.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"Express Mail" Mailing Label Number EV 740119550 US

Date of Deposit **November 1, 2006**

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman

Applicant : Stephen R. Hanson
Serial No. : 10/603,401
Filed : June 25, 2003

Attorney's Docket No.: 18852-002002/5202B
Supplemental Information Disclosure Statement

The replacement copy of Form PTO-1449 (4 pages) was previously submitted with the Information Disclosure Statements filed on July 25, 2006 and June 25, 2003. In the Office Action mailed October 12, 2006, documents B1 through C63 listed on the Form PTO-1449 were not initialed because the Examiner states that copies of the documents were not provided. 37 C.F.R. §1.98 (d) requires submission of a copy of any non-U.S. Patent document listed in an Information Disclosure Statement, **unless** the document was previously submitted to, or cited by, the US Patent and Trademark Office in an earlier application that is relied upon for an earlier effective filing date, and the earlier application is identified in the Information Disclosure Statement:

A copy of any patent, publication, pending U.S. application or other information, as specified in paragraph (a) of this section, listed in an information disclosure statement is required to be provided, even if the patent, publication, pending U.S. application or other information was previously submitted to, or cited by, the Office in an earlier application, unless:

- (1) The earlier application is properly identified in the information disclosure statement and is relied on for an earlier effective filing date under 35 U.S.C. 120; and
- (2) The information disclosure statement submitted in the earlier application complies with paragraphs (a) through (c) of this section

A copy of document C53 was submitted with the Information Disclosure Statement filed on September 13, 2005. Copies of C50 and C54 were submitted with the Information Disclosure Statement filed on July 25, 2006. The submitted copies of C50, C53 and C54 are available in the Image File Wrapper in PAIR. In accordance with 37 C.F.R. §1.98 (d), copies of documents B1 – C1, C3 – C41, C43 – C49, C51, C52 and C55 – C63 were not provided as they have been previously provided, or cited by the Examiner, in connection with U.S. Serial No. 09/666,223 (now US Patent No. 6,585,995), which is relied upon for an earlier filing date in accordance with 35 U.S.C. §120. The Forms PTO-1449 identified the parent application, serial number 09/666,223, and stated that the instant application relies on the earlier application for an earlier effective filing date under 35 USC 120. In addition, the earlier IDS complied with paragraphs (a) through (c) of 37 CFR 1.98 as evidenced by the fact that the Examiner reviewed the documents and initialed the Forms PTO-1449 (a copy of which is provided), and the references cited appear on the face of the patent that issued from the parent application. A copy of the face

Applicant : Stephen R. Hanson
Serial No. : 10/603,401
Filed : June 25, 2003

Attorney's Docket No.: 18852-002002/5202B
Supplemental Information Disclosure Statement

of US Patent No. 6,585,995, which lists documents B1 – C1, C3 – C41, C43 – C49, C51, C52 and C55 – C63 as references cited, is provided herein. Thus, Applicant has complied with the requirements of 37 CFR 1.98 and copies of the documents cited in the parent application need not be submitted in the instant application.

The documents listed on the replacement copy of the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed item is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the documents or information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97 (g) and (h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56 (b) exists.

Applicant respectfully requests that the Examiner review the foregoing documents and make them of record in the file history of the above-captioned application.

Respectfully submitted,

Stephanie Seidman
Reg. No. 38,779

Attorney Docket No. 18852-002002/5202B

Address all correspondence to:

Stephanie Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
email: seidman@fr.com



FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet 1 of 4

APPLICATION NO.: Not yet assigned

ATTY. DOCKET NO.: H00646.70001.US

FILING DATE: June 25, 2003

APPLICANT: Stephen R. Hanson

GROUP ART UNIT: Not yet assigned

EXAMINER: Not yet assigned

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	*A1	3,932,407		Beverung, Jr., et al.	01/13/76
	*A2	3,978,213		Lapinet, et al.	08/31/76
	*A3	4,088,753		Parmer	05/09/78
	*A4	4,146,718		Jenks, et al.	03/27/79
	*A5	4,206,214		Harker, et al.	06/03/80
	*A6	4,208,521		Crenshaw, et al.	06/17/80
	*A7	4,357,330		Fleming, Jr., et al.	02/02/82
	*A8	4,393,063		Moncada	07/12/83
	*A9	4,404,212		Moncada	09/13/83
	*A10	4,406,904		Welle, et al.	09/27/83
	*A11	4,432,980		Fleming, Jr., et al.	02/21/84
	*A12	4,436,934		Larock	03/13/84
	*A13	4,444,777		Fleming, Jr., et al.	04/24/84
	*A14	4,568,676		Smith	02/04/86
	*A15	4,743,445		Delwiche, et al.	05/10/88
	*A16	4,847,276		Yarrington	07/11/89
	*A17	5,185,323		Gewirtz	02/09/93
	*A18	5,306,709		Gewirtz	04/26/94
	*A19	5,391,557		Cullinan, et al.	02/21/95
	*A20	5,391,737		Reiter, et al.	02/21/95
	*A21	5,440,020		Coller	08/08/95
	*A22	5,472,944		Gewirtz, et al.	12/05/95
	*A23	5,620,960		Arnold, et al.	04/15/97
	*A24	5,789,539		Daly, et al.	08/04/98
	*A25	5,801,245		Lang	09/01/98
	*A26	6,008,232		Lakshmanan	12/28/99
	*A27	6,043,260		Chen, et al.	03/28/00
	*A28	6,103,740		Lakshmanan	08/15/00
	*A29	6,110,471		Conti, et al.	08/29/00
	*A30	6,156,753		Doherty, Jr., et al.	12/05/00
	*A31	6,287,599	B1	Burnside et al.	09/11/01
	*A32	RE 31,617		Beverung, Jr., et al.	06/26/84
	A33	6,376,242		Hanson	04/23/02

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	*B1	EP	0 260 527	A		03/23/88	Abstract
	*B2	EP	0 778 258			06/97	
	*B3	EP	0 994 114			04/00	

	*B4	EP	0 514 917			11/25/92	
	*B5	EP	0 904 783			03/99	
	*B6	HU	206 496	B		11/30/92	Abstract
	*B7	PCT	WO99/08524			02/99	
	*B8	PCT	WO99/08525			02/99	
	*B9	PCT	WO99/20223			04/99	
	*B10	PCT	WO93/23426			25/11/93	Abstract
	*B11	PCT	WO99/34792			07/15/99	
	*B12	UK	GB2,256,195			12/92	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*C1	Al-Jibouri, L.M. and Najim, R.A., "Effect of dipyridamole on blood glucose and liver cyclic AMP levels and platelet count during endotoxaemia in mice", <i>Clin. Exp. Pharmacol. Physiol.</i> , 15(7):527-32 (1988) ABSTRACT	
	*C2	Andes, et al., "Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers", <i>Thromb Haemost.</i> , 52(3):325-8 (1984)	
	*C3	Balan, K.K and Critchley, M., "Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32—a 15 year review", <i>Br. J. Radiol.</i> , 70(839):1169-73 (1997) ABSTRACT	
	*C4	Balduini, et al., "Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders", <i>Haematologica</i> , 77(1):40-3 (1992) ABSTRACT	
	*C5	Barnathan, et al., "Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty", <i>Circulation</i> , 76(1):125-134 (1987)	
	*C6	Bellucci, et al., "Positive and negative regulation of megakaryocytopoiesis", <i>C.R. Seances Soc. Biol. Fil.</i> , 190(5-6):515-32 (1996) ABSTRACT	
	*C7	Bunn, H.F., "Pathophysiology of the anemias", <i>Harrison's Principles of Internal Medicine: Hematology and Oncology</i> , 1514, 1566-67 New York, McGraw-Hill, (1991)	
	*C8	Cazenave, J.P. and Gachet, C., "Anti-platelet drugs: do they affect megakaryocytes?", <i>Baillieres Clin Haematol.</i> , 10(1):163-80 (1997)	
	*C9	Chen, et al., "Thrombospondin, a negative modulator of megakaryocytopoiesis", <i>J. Lab. Clin. Med.</i> , 129(2):231-8 (1997) ABSTRACT	
	*C10	Cortelazzo, et al., "Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis", <i>N. Engl. J. Med.</i> , 332(17):1132-6 (1995) ABSTRACT	
	*C11	Dale, et al., "Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the MpL ligand", <i>Blood</i> , 90(9):3456-3461 (1997)	
	*C12	Davies, et al., "Adverse events reported by postmenopausal women in controlled trials with raloxifene", <i>Obstetrics & Gynecology</i> , 93(4):558-565 (1999)	
	*C13	De Serres, et al., "Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man", <i>Stem Cells</i> , 17:203-209 (1999)	
	*C14	Deng, et al., "A monoclonal antibody cross-reactive with human platelets, megakaryocytes, and common acute lymphocytic leukemia cells", <i>Blood</i> , 61(4):759-764 (1983)	
	*C15	Gaver, et al., "Disposition of anagrelide, an inhibitor of platelet aggregation", <i>Clin. Pharmacol. Ther.</i> , 29(3):381-6 (1981) ABSTRACT	
	*C16	Gewirtz, et al., "Cell-mediated suppression of megakaryocytopoiesis in acquired amegakaryocytic thrombocytopenic purpura", <i>Blood</i> , 68(3):619-26 (1986) ABSTRACT	
	*C17	Glushkov, et al., "Changes in hemostatic system indices during hemosorption in healthy dogs", <i>Biull Eksp Biol. Med.</i> , 94(7):95-8 (1982) ABSTRACT	
	*C18	Goldberg, et al., "Thrombocytotoxic suppression of megakaryocyte production from stem cells", <i>Blood</i> , 49(1):59-69 (1977) ABSTRACT	
	*C19	Gugliotta, et al., "In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia", <i>Br. J. Haematol.</i> , 71(2):177-81 (1989) ABSTRACT	
	*C20	Herron, et al., "Inhibition of megakaryocytic colonies <i>in vitro</i> by anagrelide", <i>Clin. Res.</i> , 34(2):459A (1986) ABSTRACT	
	*C21	Hung, et al., "Focused antithrombotic therapy: novel anti-platelet salicylates with reduced	

		ulcerogenic potential and higher first-pass detoxification than aspirin in rats", <i>J. Lab. Clin. Med.</i> , 132(6):469-77 (1998) ABSTRACT	
*C22	Jones, et al., "Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide", <i>J. Med. Chem.</i> , 30(2):295-303 (1987) ABSTRACT		
*C23	Lecomte-Raclet, et al., "New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides", <i>Blood</i> , 91(8):2772-80 (1998) ABSTRACT		
*C24	Ludwig, et al., "Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders", <i>Cancer Immunol. Immunother.</i> , 25(3):266-73 (1987) ABSTRACT		
*C25	Mazur, et al., "Analysis of the mechanism of anagrelide -induced thrombocytopenia in humans", <i>Blood</i> , 79(8):1931-1937 (1992)		
*C26	Mazzucconi, et al., "Pipobroman therapy of essential thrombocythemia", <i>Scand J. Haematol.</i> , 37(4):306-9 (1986) ABSTRACT		
*C27	Mazzucconi, et al., "Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results", <i>Haematologica</i> , 77(4):315-7 (1992) ABSTRACT		
*C28	McCune, et al., "Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations", <i>Pharmacotherapy</i> , 17(4):822-6 (1997) ABSTRACT		
*C29	Meanwell, et al., "Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains", <i>J. Med. Chem.</i> , 35(14):2672-87 (1992) ABSTRACT		
*C30	Nagae, S. and Hori, Y., "Immune thrombocytopenia due to Tranilast (Rizaben): detection of drug-dependent platelet-associated IgG", <i>J. Dermatol.</i> , 25(11):706-9 (1998)		
*C31	Negrev, et al., "Influence of nonselective beta-adrenergic impacts on the effects of thrombocytopoietin in mice", <i>Acta Physiologica et Pharmacologica Bulgaria</i> , 13:1:35-39 (1987)		
*C32	Ramires, et al., "Effect of ticlopidine and dipyridamole on platelet aggregation and count in patients with chronic stable angina pectoris", <i>Arq Bras. Cardiol.</i> , 56(4):323-7 (1991) ABSTRACT		
*C33	Robak, T., et al., "Anagrelide—new antiplatelet drug", <i>Acta Haematol Pol.</i> , 25(4):309-15 (1994) ABSTRACT		
*C34	Sato, et al., "Multivariate analysis of risk factors for thrombus formation in University of Tokyo ventricular assist device", <i>J. Thorac. Cardiovasc. Surg.</i> , 106:520-7 (1993)		
*C35	Scott, et al., "Local delivery of an antithrombin inhibits platelet-dependent thrombosis", <i>Circulation</i> , 90(4):1951-1955 (1994)		
*C36	Sciler, et al., "Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes", <i>J. Pharmacol Exp. Ther.</i> , 243(2):767-74 (1987) ABSTRACT		
*C37	Shinagawa, et al., "Allopurinol induced pancytopenia in a patient with myeloproliferative disorder", <i>Rinsho Ketsueki</i> , 38(1):64-71 (1997) ABSTRACT		
*C38	Smith, J.B. "Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase", <i>Thromb Res.</i> , 15:28(4):477-85 (1982) ABSTRACT		
*C39	Solberg, et al., "The effects of anagrelide on human megakaryocytopoiesis", <i>Br. J. Haematol.</i> , 99(1):174-80 (1997) ABSTRACT		
*C40	Taulow, et al., "Blood platelet count and function are related to total and cardiovascular death in apparently healthy men", <i>Circulation</i> 84(2):613-617 (1991)		
*C41	Trowbridge, et al., "Platelet production in myocardial infarction and sudden cardiac death", <i>Thromb. Haemost.</i> , 52(2):167-171 (1984)		
*C42	Van de Pette, "Primary thrombocythaemia treated with busulphan", <i>Br. J. Haematol.</i> , 62(2):229-37 (1986) ABSTRACT		
*C43	van der Loo, et al., "Megakaryocytes and platelets in vascular disease", <i>Bailliere's Clinical Haematology</i> , 10(1):109-123 (1997)		
*C44	Venuti, et al., "Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazole[2,1-b]quinazoline", <i>J. Med. Chem.</i> , 31(11):2136-45 (1988) ABSTRACT		
*C45	Wada, et al., "Characterization of the truncated thrombopoietin variants", <i>Biochem. Biophys. Res. Comm.</i> , 213(3):1091-1098 (1995)		
*C46	Wadenvik, et al., "The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia", <i>Blood</i> , 77(10):2103-8 (1991) ABSTRACT		
*C47	Wilhelmsen, L., "Thrombocytes and coronary heart disease", <i>Circulation</i> 84(2):936-938 (1991)		
*C48	Yataganas, et al., "alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis", <i>Eur. J. Cancer</i> , 27 Suppl 4:S69-71 (1991) ABSTRACT		
*C49	Yeager, et al., "Effects of cyclophosphamide on murine bone marrow and splenic megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels", <i>J. Cell.</i>		

		Physiol. , 112(2):222-8 (1982) ABSTRACT		
	*C50	Harker, et al., "Regulation of Platelet Production and Function by Megakaryocyte Growth and Development Factor in Nonhuman Primates", <i>Blood</i> , Vol. 87, No. 5, pp. 1833-1844, (1996)		
	*CS1	Harker, "Platelets in Thrombotic Disorders: Quantitative and Qualitative Platelet Disorders Predisposing to Arterial Thrombosis", <i>Seminars in Hematology</i> , Vol. 35, No. 3, pp. 241-252, (1998)		
	*CS2	van der Loo, et al. " A Role for Changes in Platelet Production in the Cause of Acute Coronary Syndromes", <i>Arterioscler Thromb Vasc Biol.</i> , Vol. 19, pp. 672-679 (1999)		
	*CS3	Broudy, et al., "Thrombopoietin Stimulates Colony-Forming Unit-Megakaryocyte Proliferation and Megakaryocyte Maturation Independently of Cytokines that Signal through the gp130 Receptor Subunit," <i>Blood</i> , Vol. 8, No. 6, pp. 2026-2032 (1996)		
	*C54	Luoh, et al., "Role of the Distal Half of the CMPL Intracellular Domain or Control of Platelet Production by Thrombopoietin in Vivo," <i>Mol. Cell. Biol.</i> , Vol. 20, No. 2, pp. 507-515 (2000)		
	*C55	Landolfi, et al., "Aspirin in Polycythemia Vera and Essential Thrombocythemia: Current facts and Perspectives", <i>Leukemia and Lymphoma</i> , 1996, Vol. 22, Suppl. 1, pp. 83-86		
	*C56	Lane, et al. "Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation," <i>Experimental Hematology</i> , 2001, Vol. 29, pp. 1417-1424		
	*C57	Harker, "Platelets in Thrombotic Disorders: Quantitative and Qualitative Platelet Disorders Predisposing to Arterial Thrombosis", <i>Seminars in Hematology</i> , Vol. 35, No. 3, pp. 241-252 (1998)		
	*C58	van der Loo, et al., "A Role for Changes in Platelet Production in the Cause of Acute Coronary Syndromes", <i>Arterioscler Thromb Vasc Biol.</i> , Vol. 19, pp. 672-679 (1999)		
	*C60	Henneckens, "Update on aspirin in the treatment and prevention of cardiovascular disease" <i>Am. Heart J.</i> , 137 (4 Pt2):S9-S13 (1999) Abstract only		
	*C61	Tang, et al. "Inhibition of platelet function by antithrombotic agents which selectively inhibit low-Km cyclic 3',5'-adenosine monophosphate phosphodiesterase", <i>J. Lab.Clin. Med.</i> , 95(2):241-57 (1980)		
	*C62	Fleming, et al., "A Potent New Inhibitor of Platelet Aggregation and Experimental Thrombosis, Anagrelide (BL-4162A)", <i>Throm. Res.</i> , 15(3-4):373-88 (1979)		
	*C63	Merck Research Laboratories, N. J., "the merck manual", 1999, p. 918, column 2, paragraph 4		

EXAMINER

DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/666,223, filed September 21, 2000, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]